| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3230 |
| Trial ID | NCT05611424 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | FT-003 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Neovascular Age-related Macular Degeneration |
| Year | 2022 |
| Country | China |
| Company sponsor | Frontera Therapeutics |
| Other ID(s) | FT003WA-1 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||
|
|||||